MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-08-2023
Eagle Pharmaceuticals Retained Earnings 2011-2026 | EGRX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 112 M | 75.9 M | 84.5 M | 72.5 M | 58.2 M | 26.3 M | -25.7 M | -107 M | -104 M | -102 M | -95.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 112 M | -107 M | -527 K |
Quarterly Retained Earnings Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122 M | 117 M | 112 M | 103 M | 110 M | 120 M | 75.9 M | 82.1 M | 87.7 M | 84.1 M | 84.5 M | 84.5 M | 84.5 M | 84.5 M | 72.5 M | 72.5 M | 72.5 M | 72.5 M | 58.2 M | 58.2 M | 58.2 M | 58.2 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | -25.7 M | -25.7 M | -25.7 M | -25.7 M | -107 M | -107 M | -107 M | -107 M | -110 M | -110 M | -110 M | -110 M | - | -102 M | -102 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 122 M | -110 M | 20.2 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.14 | -1.73 % | $ 123 M |  Canada |
 |
Cronos Group
CRON
|
1.06 B | $ 2.63 | - | $ 1.38 B | Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 4.19 | -1.64 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 12.39 | 1.98 % | $ 634 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.56 | 0.07 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
-609 M | $ 6.67 | -0.07 % | $ 414 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 49.34 | -1.36 % | $ 1.61 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 1.22 | -8.65 % | $ 21.3 M |  China |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.69 | -0.88 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 6.96 | -0.43 % | $ 2.54 B | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.96 | -0.13 % | $ 55.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 5.14 | -0.77 % | $ 677 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.64 | -0.61 % | $ 3.37 M | Canada |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 26.04 | -0.12 % | $ 1.2 B | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 13.91 | -0.22 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | $ 0.44 | -2.36 % | $ 6.97 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.81 | -0.96 % | $ 18.9 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.79 | 5.63 % | $ 144 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 9.08 | -1.3 % | $ 645 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 3.54 | -2.13 % | $ 4.39 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.76 | 0.96 % | $ 235 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.63 | 3.22 % | $ 30.1 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 8.97 | -0.54 % | $ 5.54 B | Canada |
 |
Veru
VERU
|
-295 M | $ 2.13 | -1.84 % | $ 287 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 1.63 | -0.61 % | $ 17 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 12.52 | -0.2 % | $ 15.2 B | USA |
 |
cbdMD
YCBD
|
-182 M | $ 1.37 | 0.37 % | $ 5.91 M | USA |